A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers

NCT00000884 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

84

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
BIOLOGICAL: ALVAC-HIV MN120TMG (vCP205)
BIOLOGICAL: ALVAC-RG Rabies Glycoprotein (vCP65)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)